Bristol-Myers Squibb (BMY) is a global biopharmaceutical company with a market cap of $113.7 billion, serving patients worldwide with leading therapies like Eliquis and Opdivo.

Analysts expect BMY to report adjusted EPS of $1.65 for Q4 2025, down 1.2% from the year-ago quarter, but project a surge of 467.8% in adjusted EPS for fiscal 2025.

BMY stock has declined 1.7% over the past year, trailing behind market indices. Shares climbed 7.1% after the company reported strong Q3 2025 results and raised its revenue and EPS guidance for the full year.

Analysts hold a moderately optimistic consensus rating on BMY stock, with a mix of “Strong Buy,” “Moderate Buy,” “Hold,” and “Strong Sell” ratings. The stock is currently trading above the average analyst price target of $56.17.

Read more at Yahoo Finance: What You Need To Know Ahead of Bristol-Myers Squibb’s Earnings Release